Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer

PURPOSE: Previous retrospective studies reported that proton-pump inhibitors (PPIs) may decrease the efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) including gefitinib and erlotinib. Afatinib had a wider soluble pH range, with possible fewer inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Meng-Chin, Chung, Ying-Shan, Lin, Yu-Ching, Hung, Ming-Szu, Fang, Yu-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805747/
https://www.ncbi.nlm.nih.gov/pubmed/36597496
http://dx.doi.org/10.2147/OTT.S387165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805747/
https://www.ncbi.nlm.nih.gov/pubmed/36597496
http://dx.doi.org/10.2147/OTT.S387165

Ejemplares similares